Digest Network Come funziona
Network
/
Società
Al
Non verificato

Alzheon, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

18 comunicati stampa

Guarda tutti i comunicati
08/09/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Medicina - Varie
Alzheon Announces Peer-Reviewed Publication Showing Oral Valiltramiprosate/ALZ-801 Achieves Sustained Plasma Biomarker Reductions Linked to Better Cognitive, Functional, and Brain Atrophy Outcomes in APOE4 Carriers with Early Alzheimer’s Disease
Fonte
Alzheon, Inc.
Emittente
Business Wire
1.00
0
06/07/2026
Eventi
Fiere
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Medicina - Varie
Alzheon to Present New Evidence of Neurovascular Protection and Preserved Brain Microstructure from Oral Valiltramiprosate Trials in APOE4/4 Alzheimer’s Patients at AAIC 2026 Conference in London
Fonte
Alzheon, Inc.
Emittente
Business Wire
1.00
0
14/04/2026
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Medicina - Varie
Alzheon to Present Evidence of Neurovascular Protection from Trials with Oral Valiltramiprosate in APOE4/4 Alzheimer’s Patients Leading to Reduced Brain Edema and Microhemorrhage Risk at 2026 American Academy of Neurology Meeting in Chicago, Illinois
Fonte
Alzheon, Inc.
Emittente
Business Wire
1.00
0
07/04/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Medicina - Varie
Alzheon Advances Industry-Leading Portfolio of Oral Anti-Amyloid Aggregation Inhibitors with First Subject Dosed in Phase 1 of ALZ-507, Highlighting Potential for Once-Daily Administration, Improved Safety and Efficacy, and APOE4 Corrector Mechanism
Fonte
Alzheon, Inc.
Emittente
Business Wire
1.00
0
03/02/2026
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Industria
Alzheon Reports Plasma Biomarker Results from Phase 3 and 2 Studies of Valiltramiprosate/ALZ-801, Validating Its First-in-Class Mechanism of Action and Underscoring Benefits in Cognition, Function, and Brain Volume Protection in Alzheimer’s Patients
Fonte
Alzheon, Inc.
Emittente
Business Wire
1.00
0
02/12/2025
Scienza
Finanza
Medicina - Varie
Associazioni/Professionisti
Biotecnologia
Sanità
Farmaceutica
Salute
Industria
Alzheon Announces Peer-Reviewed Publication Providing Evidence for Hippocampal Volume as Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Alzheimer’s Disease
Fonte
Alzheon, Inc.
Emittente
Business Wire
1.00
0
19/11/2025
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Alzheon to Present Multiple Clinical, Neuroimaging and Modeling Results for Oral Valiltramiprosate/ALZ-801 from Phase 2 and 3 Studies at CTAD Conference in San Diego, December 1–4, 2025
Fonte
Alzheon, Inc.
Emittente
Business Wire
1.00
0
14/10/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Alzheon Announces Peer-Reviewed Scientific Publication of Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease
Fonte
Alzheon, Inc.
Emittente
Business Wire
1.00
0
15/07/2025
Salute
Sanità
Farmaceutica
Biotecnologia
Web e Social Network
Eventi
Industria
Alzheon to Present Insights into Oral Valiltramiprosate/ALZ-801 Mode of Action and Clinical Efficacy at Dedicated Symposium at Alzheimer’s Association International Conference in Toronto on July 30th, 2025
Fonte
Alzheon, Inc.
Emittente
Business Wire
1.00
0
10/04/2025
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Topline Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in Patients with Early Alzheimer’s Disease Carrying Two Copies of APOE4 Gene
Fonte
Alzheon, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0